Stockreport

Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet ne [Read more]